CharlesHRedfernMD

PubMed

• Repotrectinib in a Patient WithFusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome.
  Velasco, K., Yun, K., Narezkina, A., Redfern, C., Bazhenova, L.> ;JCO Precision Oncology. 2024 Jan 1
• 10 citations
  Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blin...
  Fred Saad, Antoine Thiery-Vuillemin, Pawel Wiechno, Boris Alekseev, Nuria Sala, Robert Jones, Ivo Kocak, Vincenzo Emanuele Chiuri, Jacek Jassem, Aude Fléchon, Charles ...> ;The Lancet. Oncology. 2022 Oct 1
• 17 citations
  A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer
  Ruth Plummer, Emma Dean, Hendrik-Tobias Arkenau, Charles H. Redfern, Alexander I. Spira, Jason M. Melear, Ki Y. Chung, Jordi Ferrer-Playan, Thomas Goddemeier, Giuseppe...> ;Lung Cancer. 2021 Dec 1
• 14 citations
  Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
  Claire F. Verschraegen, Guy Jerusalem, Edward F. McClay, Nicholas Iannotti, Charles H. Redfern, Jaafar Bennouna, Franklin Chen, Karen Kelly, Janice M. Mehnert, John C....> ;Journal for Immunotherapy of Cancer. 2020 Sep 1
• Reply to T.J.A. Dekker
  Shanu Modi, Haeseong Park, Rashmi Krishna Murthy, Hiroji Iwata, Kenji Tamura, Junji Tsurutani, Alvaro Moreno-Aspitia, Toshihiko Doi, Yasuaki Sagara, Charles H. Redfern...> ;Journal of Clinical Oncology. 2020 Jul 13
• 167 citations
  Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
  Junji Tsurutani, Hiroji Iwata, Ian E. Krop, Pasi A. Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles H. Redfern, Kenji Tamura, Trisha Wise-Draper, Kaku S...> ;Cancer Discovery. 2020 Mar 25
• 351 citations
  Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
  Shanu Modi, Haeseong Park, Rashmi Krishna Murthy, Hiroji Iwata, Kenji Tamura, Junji Tsurutani, Alvaro Moreno-Aspitia, Toshihiko Doi, Yasuaki Sagara, Charles H. Redfern...> ;Journal of Clinical Oncology. 2020 Feb 14
• 210 citations
  Trastuzumab deruxtecan (DS-8201a)in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
  Kenji Tamura, Junji Tsurutani, Shunji Takahashi, Hiroji Iwata, Ian E. Krop, Charles H. Redfern, Yasuaki Sagara, Toshihiko Doi, Haeseong Park, Rashmi Krishna Murthy, Re...> ;The Lancet. Oncology. 2019 Jun 1
• 256 citations
  Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
  Noel W. Clarke, Paweł Wiechno, Boris Alekseev, Nuria Sala, Robert H. Jones, Ivo Kocak, Vincenzo Emanuele Chiuri, Jacek Jassem, Aude Flechon, Charles H. Redfern, C. Goe...> ;The Lancet. Oncology. 2018 Jul 1
• 59 citations
  A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
  Eric J. Small, Raymond S. Lance, Thomas A. Gardner, Lawrence Karsh, Lawrence Fong, Candice McCoy, Todd DeVries, Nadeem A. Sheikh, Debraj GuhaThakurta, Nancy N. Chang, ...> ;Clinical Cancer Research. 2015 Sep 1
• Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive me...
  Stephen Eppler, Michael S. Gordon, Charles H. Redfern, Caroline Trudeau, Na Xu, Kelong Han, Bert L. Lum> ;Anti-Cancer Drugs. 2015 Apr 1
• 7 citations
  Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable s...
  Na Xu, Charles H. Redfern, Michael S. Gordon, Stephen Eppler, Bert L. Lum, Caroline Trudeau> ;Cancer Chemotherapy and Pharmacology. 2014 Oct 26
• 57 citations
  Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
  Peter D. Boasberg, Charles H. Redfern, Gregory A. Daniels, David Bodkin, Christopher R. Garrett, Alejandro D. Ricart> ;Cancer Chemotherapy and Pharmacology. 2011 Apr 24
• 3899 citations
  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
  Philip W. Kantoff, Celestia S. Higano, N. Shore, E. Roy Berger, Eric J. Small, David F. Penson, Charles H. Redfern, Anna C. Ferrari, Robert Dreicer, Robert B. Sims, Yi...> ;The New England Journal of Medicine. 2010 Jul 23
• 7 citations
  A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
  Omer N. Koc, Charles H. Redfern, Peter H. Wiernik, Fred Rosenfelt, Jane N. Winter, William D. Carter, Dan P. Gold, Morgan E. Stewart, Richard Ghalie, John F. Bender> ;Journal of Immunotherapy. 2010 Feb 1
• 233 citations
  Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ...
  Tomasz M. Beer, Christopher W. Ryan, Peter Venner, Daniel P. Petrylak, Gurkamal Chatta, J. Dean Ruether, Charles H. Redfern, Louis Fehrenbacher, Mansoor N. Saleh, Davi...> ;Journal of Clinical Oncology. 2007 Feb 9
• 73 citations
  Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin’s Lymphoma Resulting in Durable Clinical Responses
  Charles H. Redfern, Troy H. Guthrie, Alberto Bessudo, John J. Densmore, Peter Holman, Nalini Janakiraman, John P. Leonard, Richard Levy, Richard G. Just, Mitchell R. S...> ;Journal of Clinical Oncology. 2006 Jul 1
• 874 citations
  Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer
  Eric J. Small, Paul F. Schellhammer, Celestia S. Higano, Charles H. Redfern, John Nemunaitis, Frank H. Valone, Suleman S. Verjee, Lori A. Jones, Robert M. Hershberg> ;Journal of Clinical Oncology. 2006 Jul 1
• GCS-100, a galectin-3 antagonist, in refractory solid tumors: A phase I study.
  Grous JJ, Redfern CH, Mahadevan D, Schindler J> ;J. Clin. Oncol.. 2006-06-20
• A phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL).
  Gribben JG, Stephenson JJ, Bartlett NL, Milder MS, Boccia RV, Redfern C, Mizuno VM, Hillson J, Berenson RJ, Frohlich MW> ;J. Clin. Oncol.. 2005-06-01
• Successful anti-Id T-cell responses to Id-KLH immunotherapy in B-cell depleted patients with follicular lymphoma (FL) may prolong TTP after rituximab: Phase II trial o...
  Koc ON, Redfern C, Wiernik P, Rosenfelt F, Winter J, Guthrie T, Kaplan L, Holman P, Densmore J, Hainsworth J> ;J. Clin. Oncol.. 2004-07-15
• 45 citations
  Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer.
  Yoo-Joung Ko, Glenn J. Bubley, Robert Weber, Charles H. Redfern, Daniel P. Gold, Lothar Finke, Andreas Kovar, Thomas A. Dahl, Stephen Gillies> ;Journal of Immunotherapy. 2004 May 1
• 5 citations
  Tools for dissecting signaling pathways in vivo: Receptors activated solely by synthetic ligands
  Kimberly Scearce-Levie, Peter Coward, Charles H. Redfern, Bruce R. Conklin> ;Methods in Enzymology. 2002 Jan 1
• 44 citations
  Engineering receptors activated solely by synthetic ligands (RASSLs).
  Kimberly Scearce-Levie, Peter Coward, Charles H. Redfern, Bruce R. Conklin> ;Trends in Pharmacological Sciences. 2001 Aug 1
• 22 citations
  Abnormal contraction caused by expression of Gi-coupled receptor in transgenic model of dilated cardiomyopathy
  Anthony J. Baker, Charles H. Redfern, Mark D. Harwood, Paul C. Simpson, Bruce R. Conklin> ;American Journal of Physiology. Heart and Circulatory Physiology. 2001 Apr 1
• Join now to see all